Inhibitors of SARS-Coronavirus-2 infection

Description of the granted funding

Pharmaceutical interventions to decrease COVID-19 severity and lethality are urgently needed globally. Our multidisciplinary consortium is focused to develop therapies for COVID-19 at University of Helsinki and VTT using different approaches: by cloning and producing human antibodies cloned from individual immune cells from the patients recovered from COVID-19 disease, and by screening safe-in-human compounds for SARS-CoV-2 inhibitory effects in in vitro systems. Structural studies will produce information of SARS-CoV-2 binding at the molecular level, informing also further engineering of the binding antibodies. Animal models of SARS-CoV-2 infection will be developed for further in vivo testing of the inhibitors.
Show more

Starting year

2020

End year

2022

Granted funding






Olli Kallioniemi Orcid -palvelun logo
220 792 €

Role in consortium of the Academy of Finland

Partner

Other consortium parties

Partner
University of Helsinki (336494)
192 617 €
Partner
VTT Technical Research Centre of Finland Ltd (336495)
219 256 €
Partner
University of Helsinki (336492)
238 620 €
Partner
University of Helsinki (336493)
189 926 €
Leader
University of Helsinki (336490)
499 937 €

Funder

Research Council of Finland

Funding instrument

Targeted Academy projects

Other information

Funding decision number

336496

Fields of science

Plant biology, microbiology, virology

Research fields

Mikrobiologia

Themes

Lisätalousarvio III 2020

Identified topics

covid, pandemic, vaccines